JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms
Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commercial franchises.
The bank’s analysts, led by Jessica Fye, noted that several firms have already achieved sustained profitability, while others are on the verge, setting the stage for margin expansion and long-term growth.
The report highlighted that companies such as Alnylam Pharmaceuticals Inc (NASDAQ: ALNY), BeOne Medicines AG DRC (NASDAQ: ONC), and Ascendis Pharma AS (NASDAQ: ASND) have transitioned into profitability, while Insmed and Ionis are close to doing so. JPMorgan sees diversification as another key theme, with Vertex Pharmaceuticals expanding into renal disease, BioMarin strengthening its rare disease portfolio through acquisitions, and Moderna applying its mRNA platform to oncology.
Analysts also pointed to a steady stream of clinical updates ahead, including high-profile cardiovascular outcomes trials for Ionis’s partnered drugs and pivotal renal readouts from Vertex, which could act as catalysts for the sector.
JPMorgan rated Vertex Pharmaceuticals Inc (NASDAQ: VRTX), Alnylam, BeOne, United Therapeutics Corporation (NASDAQ: UTHR), Insmed Inc (NASDAQ: INSM), Ascendis, Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), Ionis, BioMarin, and Mirum “Overweight,” while assigning “Neutral” ratings to BioNTech, Incyte, and Halozyme. Moderna was rated “Underweight,” with analysts citing financial risks despite progress in oncology.
Price targets for December 2026 include $515 for Vertex, $420 for Alnylam, $415 for BeOne, $685 for United Therapeutics, and $180 for Insmed. Moderna was given a $40 target, while BioNTech was set at $100.
The analysts emphasized that the sector is strategically positioned for growth, with companies broadening their commercial footprints and pursuing disciplined business development. “Several biotechs are converting pipeline success into profitable franchises,” the report stated, underscoring confidence in the group’s ability to scale beyond single-product reliance.
With profitability momentum, diversification, and clinical catalysts converging, JPMorgan sees the large-cap biotech sector entering a new phase of durable expansion.